Introduction
============

Renal cancer is one of the ten most common cancers in the west, with an annual incidence of 2 % to 4 % [@B1]. Approximately 90% of renal cancers are renal cell carcinoma (RCC), most of which (70 % - 85 %) are clear cells subtype (ccRCC) [@B2]. According to tumor size, the extent of invasion outside of the kidney, lymph node involvement and tumor metastasis, RCC can be classified into four different pathological stages , including stage I, stage II, stage III, stage IV [@B3]. The higher pathological stage leads to lower survival rate of the patients with RCC and the five-year survival rates of the four stages are 95%, 88%, 59% and 20%, respectively [@B4]. Localized renal cell carcinoma can be cured by surgery treatment, however, the survival rate of patients sharply declined once the disease became metastatic. ccRCC is usually resistant to chemotherapy, targeted therapies have been exploited for their target specificity and low toxicity, so they can be the best choice of non-surgical treatments [@B5]. Many of them have been approved for clinical use such as multi-kinase inhibitors, anti-VEGF antibodies and mTOR [@B6]. Survival of patients indeed have been improved by the new therapies, however, median progression-free and overall survival are nearly 2 years, most patients eventually become resistance and surrender [@B5]. Therefore, more effective biomarkers and therapeutic targets are urgent needed.

At present, with the development of high-throughput microarray technology, gene expression profiles have been used to identify genes associated with progression of renal cancer [@B7]-[@B9]. However, most studies focused on the screening of differentially expressed genes and ignored the high degree of interconnection between genes, although genes with similar expression patterns may be functionally related [@B10]. Weighted gene co-expression network analysis (WGCNA) has been used to investigate the associations between gene sets and clinical charactaristics by constructing scale free gene co-expression networks [@B11]. Recently, many studies have performed WGCNA using microarray or RNA sequencing data to screen hub genes and modules related with clinical characteristics such as tumor stage, grade and metastasis among different tumor types including papillary renal cell carcinoma [@B12] and hepatocellular carcinoma [@B13]. Thus, we attempt to construct a co-expression network of relationships between genes through a systematic biology method based on a weighted genome expression network (WGCNA) and to identify network-centric genes associated with different stages of disease progression of renal cancer [@B14]-[@B16].

Materials and Methods
=====================

Data collection
---------------

A workflow of the study was shown in Figure [1](#F1){ref-type="fig"}. Microarray dataset of clear cell renal cell carcinoma was downloaded from Gene Expression Omnibus (GEO) database (*<http://www.ncbi.nlm.nih.gov/geo/>*). Dataset GSE66272 [@B17] performed on Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA) was used to construct co-expression networks and identify hub genes in this study. This dataset included 27 normal kidney tissues and 26 ccRCC tissues with different pathological stages (I - IV), tumor grades (grade 1 - 4) and metastasis (yes or no) (Figure [2](#F2){ref-type="fig"}). One sarcoma sample GSM1618417 was removed from the subsequent analysis in the GSE66272. Another independent dataset of GSE53757 [@B18] was also downloaded from GEO and used as a test set to verify our results. This dataset included 72 normal kidney tissues and 72 ccRCC tissues with different tumor stages (1-4). Moreover, RNA-sequencing data sets and clinical information were downloaded from The Cancer Genome Atlas (TCGA) database (*<https://genome-cancer.ucsc.edu/>*) to further verify our results. The gene expression data were based on the RNA-sequencing technology of IlluminaHiseq. The detailed information of the training dataset and the two testing datasets was shown in Supplementary Table [1](#SM0){ref-type="supplementary-material"}.

Data preprocessing
------------------

Raw microarray data were performed RMA background correction and log2 transformed then normalized by quantile normalization. Median-polish probesets were summarized by using the "Affy" R package [@B19]. At last, probes were annotated by the Affymetrix annotation files. Microarray quality was assessed by sample clustering according to the distance between different samples in Pearson\'s correlation matrices and average linkage.

Differentially expressed genes (DEGs) screening
-----------------------------------------------

The "limma" \[20\]R package was used to screen the DEGs between normal kidney and ccRCC tissues in the expressing data. The SAM (significance analysis of microarrays) with FDR (false discovery rate) \< 0.05 and \|log2 fold change (FC)\| \> 1 were applied to select genes further considered in the network construction.

Co-expression network construction
----------------------------------

Firstly, expression data profile of DEGs was tested to check if they were the good samples and good genes. Then, we used the "WGCNA" package in R to construct co-expression network for the DEGs [@B21], [@B22]. At first, the Pearson\'s correlation matrices were both performed for all pair-wise genes. Then, a weighted adjacency matrix was constructed using a power function a~mn~ = \|c~mn~\|^β^ (c~mn~ = Pearson\'s correlation between gene m and gene n; a~mn~ = adjacency between gene m and gene n). β was a soft-thresholding parameter that could emphasize strong correlations between genes and penalize weak correlations. Here, the power of β = 6 (scale free R^2^ = 0.85) was selected to ensure a scale-free net-work (Figure [3](#F3){ref-type="fig"}). Next, the adjacency was transformed into topological overlap matrix (TOM), which could measure the network connectivity of a gene defined as the sum of its adjacency with all other genes for network generation [@B23]. To classify genes with similar expression profiles into gene modules, average linkage hierarchical clustering was conducted according to the TOM-based dissimilarity measure with a minimum size (gene group) of 30 for the genes dendrogram [@B24]. To further analyze the module, we calculated the dissimilarity of module eigengenes, chose a cut line for module dendrogram and merged some module.

Identification of clinical significant modules and functional annotation
------------------------------------------------------------------------

Two approaches were used to identify modules related with the progression of ccRCC. First, Gene significance (GS) was defined as the log10 transformation of the P value (GS = lgP) in the linear regression between gene expression and pathological stage. In addition, module significance (MS) was defined as the average GS for all the genes in a module. In general, the module with the absolute MS ranked first or second among all the selected modules was considered as the one related with clinical trait. Module eigengenes (MEs) were considered as the major component in the principal component analysis for each gene module and the expression patterns of all genes could be summarized into a single characteristic expression profile within a given module. In addition, we calculated the correlation between MEs and clinical trait to identify the relevant module. In order to explore the potential mechanism of how module genes impact correlative clinical feature, we uploaded all genes in blue module into the DAVID database and performed GO functional enrichment analysis [@B25], [@B26]. False discovery rate (FDR) \< 0.01 was set as the cutoff criteria.

Identification of hub genes
---------------------------

Hub genes, highly interconnected with nodes in a module, have been shown to be functionally significant. In our study, we chose an interesting module, and hub genes were defined by module connectivity, measured by absolute value of the Pearson\'s correlation (cor.geneModuleMembership \> 0.8) and clinical trait relationship, measured by absolute value of the Pearson\'s correlation (cor.geneTraitSignificance \> 0.2) [@B21], [@B27]. Hub genes in the module were defined as highly correlated with certain clinical trait. Furthermore, protein-protein interaction (PPI) network was constructed by uploading all genes in the hub module to the STRING (Search Tool for the Retrieval of Interacting Genes) [@B28], [@B29]. A combined score of ≥ 0.8 was regard as positive interaction between genes and a connectivity degree of ≥ 15 was defined as hub genes in PPI network. The common hub genes in both co-expression network and PPI network were regarded as "real" hub genes for further analyses.

Survival analysis and efficacy evaluation
-----------------------------------------

The test set of GSE53757 was analyzed and a linear regression analysis was performed to calculate the relationship between the hub genes expressions and the pathological stages of ccRCC. Besides, RNA-sequencing data sets including 539 ccRCC samples were analyzed to compare expression of FCER1G between different pathological stages of ccRCC.

For survival analysis, 539 patients were dichotomized into two groups according to FCER1G expression (high vs. low). Then we used R package "survival" to implement log-rank tests and generate Kaplan-Meier survival curve [@B30]. ROC curve was plotted and AUC was calculated with "ROCR" package [@B31]. When AUC value was greater than 0.7, the hub gene was considered capable of distinguishing localized (pathological stage I/II) and nonlocalized (pathological stage III/IV) ccRCC with excellent specificity and sensitivity. In addition, another two databases including Oncomine (*<http://www.oncomine.org>*), The Human Protein Atlas (*<http://www.proteinatlas.org>*) [@B32] were used to validate candidate gene expression.

Gene set enrichment analysis (GSEA)
-----------------------------------

539 ccRCC samples from RNA-sequencing data were divided into two groups (high vs. low) according to the expression level of FCER1G and median expression value was used as the cut-off point. In order to figure out potential function of FCER1G, GSEA (<http://software.broadinstitute.org/gsea/index.jsp>) [@B33] was performed between the two groups. Annotated gene sets c2.cp.kegg.v5.2.symbols.gmt was chosen as the reference gene sets. FDR \< 0.05, \|enrichment score (ES) \| \> 0.6 and gene size ≥ 100 were set as the cut-off criteria.

Results
=======

DEGs screening
--------------

A workflow of the study was shown in Figure [1](#F1){ref-type="fig"}. After data preprocessing and quality assessment, the expression matrices were obtained from the 54 samples in training set GSE66272. Under the threshold of FDR\< 0.05 and \|log2FC\| \> 1, a total of 4042 DEGs (2134 up-regulated and 1908 down-regulated) were screened out and selected for subsequent analysis.

Weighted co-expression network construction and key modules identification
--------------------------------------------------------------------------

26 ccRCC samples with complete clinical data were included in co-expression analysis (Figure [2](#F2){ref-type="fig"}). We used "WGCNA" package in R to put the DEGs with similar expression patterns into modules by average linkage clustering. In current study, the power of β = 6 (scale free R^2^ = 0.85) was selected as the soft-thresholding to ensure a scale-free network (Figure [3](#F3){ref-type="fig"}), and a total of 12 modules were identified (Figure [4](#F4){ref-type="fig"}A). Identifying modules most significantly associated with clinical features had great biological significance. The highest association in the Module-feature relationship was found between blue module and pathological stage (r = -0.77, p = 5e-6; Figure [4](#F4){ref-type="fig"}B), which were selected as module of interest and clinical feature to be studied in subsequent analyses. The module of interest was also associated with tumor grade and metastasis.

In order to explore biological relevance of blue module, 544 genes in blue module were enriched using DAVID database for Gene Ontology (GO) analyses. Biological processes of blue module were suggested to focus on inflammatory response (p = 5.293e-19), immune response (p = 5.262e-15), innate immune response (p = 6.072e-08) and chemotaxis (p = 7.844e-06, Figure [5](#F5){ref-type="fig"}A).

Hub gene identification
-----------------------

Defined by module connectivity, measured by absolute value of the Pearson\'s correlation (cor.geneModuleMembership \> 0.8) and clinical trait relationship, measured by absolute value of the Pearson\'s correlation (cor.geneTraitSignificance \> 0.2). In this study, 38 genes with the high connectivity in blue module were taken as hub genes (Table [1](#T1){ref-type="table"}). Moreover, we also constructed a network of protein-protein interaction (PPI) for all genes in blue module by Cytoscape according to the STRING database (*<https://string-db.org/>*) and genes connected with more than 15 nodes were identified as hub genes in the PPI network (Figure [5](#F5){ref-type="fig"}B). The three common hub genes (FCER1G, TYROBP and PTAFR) in both co-expression network and PPI network were regarded as"real" hub genes for further validation (Table [1](#T1){ref-type="table"}).

Hub gene validation
-------------------

The three common hub genes (FCER1G, TYROBP and PTAFR) were selected for validation. In training set GSE66272, FCER1G had a higher correlation (r = 0.955) with the disease progression than another two genes (r = 0.921 and 0.878, Table [1](#T1){ref-type="table"}). Therefore, FCER1G was chosen as the candidate gene for further validation. In the test set GSE53757, linear regression analyses were conducted to validate FCER1G, showing that FCER1G expression had a strong positive correlation with four ccRCC stages (p = 0.000146, Figure [6](#F6){ref-type="fig"}A). ROC curve validated that FCER1G could distinguish localized (pathological stage I, II) from non-localized (pathological stage III, IV) ccRCC (p \< 0.001, AUC = 0.743). In addition, based on RNA-sequencing data, one-way ANOVA and an independent sample t test were performed and suggesting that expression of FCER1G could also effectively distinguish localized ccRCC (pathological stage I or II) from non-localized ccRCC (pathological stage III or IV) (Figure [6](#F6){ref-type="fig"}C). Also based on RNA-sequencing data, patients with higher expression of FCER1G showed significantly shorter overall survival time, indicating that FCER1G was also a prognosis biomarker of ccRCC (Figure [6](#F6){ref-type="fig"}D). Moreover, FCER1G was suggested to be correlated with clinical parameters in ccRcc (Supplementary Table [2](#SM0){ref-type="supplementary-material"}). In addition, FCER1G mRNA and protein expression were both significantly higher in ccRCC tissue compared with normal kidney tissues (Figure [6](#F6){ref-type="fig"}E-F, Supplementary Figure [1](#SM0){ref-type="supplementary-material"}B-C), which was suggested by the two testing datasets: Oncomine database and The Human Protein Atlas database.

Gene set enrichment analysis
----------------------------

To obtain further insight into the function of the hub gene, GSEA was conducted to map into KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways database. Under the cut-off criteria FDR \< 0.05, \|enrichment score (ES) \| \> 0.6 and gene size ≥ 100, a total of 12 functional gene sets were enriched, and most of the gene sets focused on immune related pathways. Six representative pathways were "Antigen processing and presentation", "Cell adhesion molecules cams", "Chemokine signaling pathway", "FC gamma r mediated phagocytosis", "T cell receptor signaling pathway" and "Toll like receptor signaling pathway" (Figure [7](#F7){ref-type="fig"}).

Discussion
==========

FCER1G, also known as FcRγ, is a key molecule involved in allergic reactions [@B34]. Currently only a few studies reported the function role of FCER1G. Pauline A. et al reported that FCER1G was essential for tumor development and squamous carcinogenesis by activating FCER1G that was required for establishing chronic inflammatory programs [@B35]. Yutaka K. *et al* suggested that FCER1G acted as an important role in death-activating signal then induced cell apoptosis [@B36].

WGCNA constructed a gene co-expression network to provide a global interpretation of gene expression information based on the similarity of the expression profiles in the sample. Many of the articles related to WGCNA had been published in well-known journals in the field of biological information and systems biology [@B11], [@B37], [@B38]. The WGCNA algorithm had been used to identify complex disease-related genes, biological pathways and tumor therapy targets such as familial combination of hyperlipidemia [@B39], Alzheimer\'s disease [@B40] and osteoporosis [@B41]. To the best of our knowledge, this is the first attempt to use WGCNA to identify hub gene as biomarkers capable of distinguishing localized from non-localized ccRCC.

In this study, WGCNA was performed to identify gene co-expression modules related with the progression of ccRCC. The blue module was identified, and 38 hub genes were screened from the module. Further analysis was preformed and three common hub genes (FCER1G, TYROBP and PTAFR) in both co-expression network and PPI network were regarded as "real" hub genes for further validation, indicating that the three hub genes had high connection with clinical trait as well as vital biological processes.

In the training set, TYROBP and PTAFR showed a moderate correlation with the progression of ccRCC, and only FCER1G was highly correlated with the clinical trait estimated by log rank test (p \< 0.001). In the test set, FCER1G was positively correlated with the pathological malignant of renal cell carcinoma (Figure [6](#F6){ref-type="fig"}A). Additionally, ROC curve indicated that FCER1G exhibited excellent diagnostic efficiency for localized and non-localized ccRCC (AUC \> 0.7, Figure [6](#F6){ref-type="fig"}B). One-way ANOVA and an independent sample t test were performed using RNA-sequencing data suggested that expression of FCER1G could effectively distinguish localized ccRCC (pathological stage I or II) from non-localized ccRCC (pathological stage III or IV). Recent studies have implied that the prognosis of nonlocalized RCC was significantly lower than that of localized RCC [@B42]. Therefore, genes related to pathological stage were supposed to be associated with prognosis. We then performed survival analysis to validate if FCER1G was associated with patient prognosis, revealing FCER1G expression was significantly associated with prognosis (p \< 0.05).

Besides, through the Oncomine database and the two testing datasets, we could also find a significant higher expression of FCER1G in ccRCC tissues than normal kidney tissues. Immunohistochemistry staining of FCER1G protein was also significantly higher in renal carcinoma compared with normal kidney, revealed by the Human Protein Atlas database. Considering the functional role of FCER1G, it showed a simulative role in carcinogenesis mainly by correlating with immune reactions. As mentioned above, FCER1G was essential in chronic inflammatory programs and acted as an important role in death-activating signal then induced cell apoptosis. Meanwhile, in gene set enrichment analysis, we also found that the gene sets associated with immune-related pathways were enriched in the samples with FCER1G highly expressed. There was currently no relative reports concerning the association between FCER1G and carcinoma, however, it was generally conceded that chronic inflammatory was closely related to oncogenesis. Therefore, we might assume that overexpressed FCR1G regulated immune-related pathways to tumorigenesis.Some limitations of this study should be mentioned. In the present study, several risk factor such as age, gender, pathological stage, tumor grade and metastasis were included for analysis in patients with ccRCC, However, other major established risk factors for RCC contained excess body weight, hypertension and cigarette smoking [@B4], were not included for analysis due to limitation during data collection. Besides, a large number of clinical samples are required to validate our findings and elucidate the underlying mechanisms of how FCER1G impact on pathological stage.

In summary, our study used systems biology-based WGCNA to construct a gene co-expression network, identify and validate network hub genes associated with the progression of ccRCC. Eventually, FCER1G was identified and validated in association with the progression of ccRCC, which was also capable of distinguishing localized from non-localized ccRCC. These results are of great clinical significance and will contribute to personalized therapy.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures and tables.

###### 

Click here for additional data file.

The excellent technical assistance of Shanshan Zhang and Danni Shan is gratefully acknowledged. This study was supported in part by grants from Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (cxpy20160010) and Natural Sciences Foundation of Hubei Province (2014CFA006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

![Flow chart of data preparation, processing, analysis and validation in this study.](ijbsv13p1361g001){#F1}

![**Clustering dendrogram of 26 tumor samples and the clinical traits.** The clustering was based on the expression data of differentially expressed genes between tumor samples and non-tumor samples in ccRCC. The red color represented metastasis and female. The color intensity was proportional to older age as well as higher pathological stage and tumor grade.](ijbsv13p1361g002){#F2}

![**Determination of soft-thresholding power in the weighted gene co-expression network analysis (WGCNA). (A)** Analysis of the scale-free fit index for various soft-thresholding powers (β). **(B)** Analysis of the mean connectivity for various soft-thresholding powers. **(C)** Histogram of connectivity distribution when β = 6. **(D)** Checking the scale free topology when β = 6.](ijbsv13p1361g003){#F3}

![**Identification of modules associated with the clinical traits of ccRCC. (A)** Dendrogram of all differentially expressed genes clustered based on a dissimilarity measure (1-TOM). **(B)** Heatmap of the correlation between module eigengenes and clinical traits of ccRCC. **(C)** Distribution of average gene significance and errors in the modules associated with pathological stage of ccRCC.](ijbsv13p1361g004){#F4}

![**Go functional enrichment and protein-protein interaction network of genes in the blue module. (A)** Go functional enrichment of genes in the blue module. The x-axis shows the number of genes and the y-axis shows the GO terms. The -log10 (P-value) of each term is colored according to the legend. **(B)** Protein-protein interaction network of genes in the blue module. The color intensity in each node was proportional to variation of expression in comparison to non-tumor samples (up-regulation in red and down-regulation in purple). The nodes with bold circle represented network hub genes identified by WGCNA.](ijbsv13p1361g005){#F5}

![**Validation of FCER1G. (A)** The correlation of FCER1G expression with the pathological stage of ccRCC (based on microarray data of GSE53757). **(B)** Receiver operating characteristic (ROC) curves and area under the curve (AUC) statistics to evaluate the diagnostic efficiency of the FCER1G in GSE53757 data to distinguish between localized and non-localized ccRCC. **(C)** Boxplots of FCER1G across different pathological stages in the TCGA data set. The boxplots show the medians and dispersions of the samples of different pathological stages for FCER1G, where the scattered black spots represent the expression level of the FCER1G. P-values are the results of independent sample T-test between pathological stage I and II, pathological stage III and IV, pathological stage II and III, pathological stage I/II and III/IV and one-way ANOVA for different pathological stages. **(D)** Survival analyses of FCER1G in the TCGA data set. **(E)** FCER1G mRNA expression was significantly higher in ccRCC tissues compared with normal kidney tissues based on Oncomine database. **(F)** FCER1G protein was strongly up-regulatedin renal carcinoma tissues compared with normal kidney based on The Human Protein Atlas database. The normal kidney tissue was from a male, aged 16 (patient ID: 1767; staining: low; intensity: moderate; quantity: \< 25%; location: nuclear) and the kidney carcinoma tissue was from a female, aged 70 (patient ID: 1498; staining: medium; intensity: moderate; quantity: \> 75%; location: nuclear).](ijbsv13p1361g006){#F6}

![**Gene set enrichment analysis (GSEA).** Only listed the six representative functional gene sets enriched in clear cell renal cell carcinoma with FCER1G highly expressed.](ijbsv13p1361g007){#F7}

###### 

Hub genes in the module related with pathological stage.

  ------------------------------------------------------------------------------------------------
  Gene       Probe           Co-expression analysis\      Hub gene in\   DEG analysis   
                             (cor.geneModuleMembership)   PPI network                   
  ---------- --------------- ---------------------------- -------------- -------------- ----------
  FCER1G     204232_at       0.955                        YES            3.29           3.98E-20

  TYROBP     204122_at       0.921                        YES            3.43           3.98E-20

  PTAFR      227184_at       0.878                        YES            1.52           2.26E-13

  LAPTM5     201720_s\_at    0.936                        NO             3.53           4.40E-21

  LAIR1      208071_s\_at    0.932                        NO             3.33           5.05E-21

  C1QC       225353_s\_at    0.910                        NO             4.10           5.05E-21

  CD86       205685_at       0.845                        NO             3.16           7.26E-21

  FCGR3A     204006_s\_at    0.859                        NO             4.07           4.87E-20

  FCGR1A     216950_s\_at    0.898                        NO             3.33           2.19E-18

  TNFSF13B   223501_at       0.839                        NO             2.84           3.65E-18

  CTSS       232617_at       0.860                        NO             3.09           4.66E-18

  CD14       201743_at       0.848                        NO             2.53           1.03E-17

  MS4A7      223343_at       0.829                        NO             3.52           2.05E-17

  FPR3       230422_at       0.820                        NO             3.35           3.38E-17

  EVI2A      204774_at       0.821                        NO             2.97           5.35E-17

  TM6SF1     219892_at       0.829                        NO             3.00           1.47E-16

  C1orf162   228532_at       0.824                        NO             3.04           1.76E-16

  FCGR1B     214511_x\_at    0.898                        NO             3.33           2.19E-18

  HCK        208018_s\_at    0.913                        NO             2.49           1.96E-16

  LILRB1     211336_x\_at    0.848                        NO             3.06           3.12E-16

  PLEK       212146_at       0.834                        NO             2.73           6.28E-16

  TLR2       204924_at       0.803                        NO             2.78           7.86E-16

  TLR7       220146_at       0.809                        NO             3.01           4.03E-15

  LILRB2     207697_x\_at    0.842                        NO             3.04           1.85E-14

  SLC15A3    219593_at       0.871                        NO             2.78           2.09E-14

  CD300LF    1553043_a\_at   0.814                        NO             3.90           4.83E-14

  TBXAS1     208130_s\_at    0.825                        NO             1.88           2.21E-13

  LY86       1553428_at      0.834                        NO             2.70           1.64E-19

  MS4A6A     219666_at       0.830                        NO             2.75           3.70E-19

  C1QA       218232_at       0.896                        NO             3.66           4.08E-19

  C1QB       202953_at       0.899                        NO             3.78           5.20E-19

  TREM2      219725_at       0.833                        NO             5.06           6.32E-19

  SRGN       1554676_at      0.843                        NO             2.38           1.22E-18
  ------------------------------------------------------------------------------------------------
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